Leica Biosystems, based in Nussloch, Germany, establish its US-based research and development laboratory facility in Danvers, Massachusetts, north of Boston.
The firm is a global leader in workflow solutions and automation, striving to advance cancer diagnostics. Leica Biosystems said it provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting.
Citing the state’s global leadership in the life sciences and a growing customer base in the United States, Leica said its presence in Massachusetts will focus on research and development of companion diagnostics. The company’s temporary offices and R&D lab space are in Danvers, Mass., with plans to expand by the end of the year.
“We are delighted to announce the opening of the Leica Biosystems R&D facility in Boston,” said Matthias Weber, M.D., President of Leica Biosystems. “Being in Massachusetts gives us the ability to collaborate closely with the pharmaceutical industry on a domestic level, and this was a major influence in choosing Boston as our U.S. R&D location. We are already seeing the benefit of our decision, and look forward to our second round of recruitment in 2013.”
“Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences,” said Governor Deval Patrick. “We welcome Leica Biosystems to the Commonwealth and look forward to them creating jobs and economic opportunities here in Massachusetts.”
Through the Massachusetts Life Sciences Center, Massachusetts is investing $1 billion over 10 years in the growth of the state’s life sciences supercluster. These investments are being made under the Massachusetts Life Sciences Initiative, proposed by Governor Patrick in 2007, and passed by the State Legislature and signed into law by Governor Patrick in 2008.
“We are excited to welcome Leica Biosystems to the fast-growing Massachusetts life sciences community,” said Susan Windham-Bannister, Ph.D., President and CEO of the Massachusetts Life Sciences Center. “With its cutting-edge cancer diagnostics technology and processes for histology and tissue processing, Leica Biosystems will be an important partner for the Commonwealth’s R&D-focused organizations in both industry and academia.”
“Massachusetts has become the destination for the world’s most innovative companies across the entire life sciences spectrum,” said Robert K. Coughlin, President and CEO of MassBio. “We are thrilled to welcome Leica Biosystems and know they will play a very important role in our world-class life sciences ecosystem.”